A 360 degree perspective on the impact of biosimilars
Paul O'Meara, Amanda Baskett, Alessandra Franceschetti and Sam MentzerIpsos Healthcare
Summary
Given the ongoing introduction of 'biosimilars' (subsequent versions of innovator biopharmaceuticals created by a different manufacturer following patent expiry), it is critical to understand how these products will impact current treatment practices – both for the originators of branded products and for those developing biosimilar options.
Ipsos Healthcare's syndicated Autoimmune Biosimilar Impact Study delivers a comprehensive, future-focused solution to this common need. It combines perceptual research among doctors and payers with robust patient-level data from Ipsos' Global Therapy Monitors....